Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.73 |
| ▸ | RAB9A | P51151 | 5/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | CASP3 | P42574 | 1/20 | 0.69 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.69 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.69 |
| ▸ | PLG | P00747 | 3/20 | 0.68 |
| ▸ | KLK1 | P06870 | 2/20 | 0.68 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.64 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | NPY1R | P25929 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743095 | 1.00 | NPC1 (0.73) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL30637146 | 1.00 | NPC1 (0.73) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL5426499 | 0.92 | KMT2A (0.84) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL11059810 | 0.89 | NPC1 (0.60) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL330715 | 0.88 | TMPRSS4 (0.65) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL15478030 | 0.87 | KMT2A (0.77) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL30084384 | 0.87 | MEN1 (0.77) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL29890853 | 0.87 | MEN1 (0.77) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL57970 | 0.87 | MEN1 (0.77) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL2129113 | 0.85 | FADS1 (0.71) | NPC1RAB9AMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230073777-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-03-09 | — | — | US | claimed |
| EP-4692249-A1 | COLORING AGENT, COLORING COMPOSITION, AND METHOD FOR PRODUCING COLORING AGENT | Artience Co., Ltd. (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-10-23 | — | — | US | disclosed |
| CN-116507333-B | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250064841-A1 | Aqueous Composition Comprising Avermectins | HWI PHARMA SERVICES GMBH (DE) | 2025-02-27 | — | — | US | disclosed |
| CN-119330963-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4460296-A1 | AQUEOUS COMPOSITION COMPRISING AVERMECTINS | HWI pharma services GmbH (DE) | 2024-11-13 | — | — | EP | disclosed |
| WO-2024204597-A1 | COLORING AGENT, COLORING COMPOSITION, AND METHOD FOR PRODUCING COLORING AGENT | ａｒｔｉｅｎｃｅ株式会社 | 2024-10-03 | — | — | WO | disclosed |
| CN-118510506-A | Aqueous composition comprising avermectin | 荷维制药服务有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20230416191-A1 | Compounds, Compositions and Methods for the Treatment of CREB-dependent Diseases | Sereno Sciences, Inc. | 2023-12-28 | — | — | US | disclosed |
| CN-116850165-A | Use of compounds and pharmaceutically acceptable salts thereof in anti-coronavirus | 广州国家实验室 | 2023-10-10 | — | — | CN | disclosed |
| CN-116507333-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023131584-A1 | AQUEOUS COMPOSITION COMPRISING AVERMECTINS | HWI PHARMA SERVICES GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
| EP-4209212-A1 | AQUEOUS COMPOSITION COMPRISING AVERMECTINS | HWI pharma services GmbH (DE) | 2023-07-12 | — | — | EP | disclosed |
| US-11674963-B2 | GPCRs in cancer-associated fibroblasts | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-13 | — | — | US | disclosed |
| CN-115990161-A | Application of dihydro-beta-agarofuran sesquiterpenoids | 上海市伤骨科研究所 | 2023-04-21 | — | — | CN | disclosed |
| US-20230073777-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-03-09 | — | — | US | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416191-A1 | Compounds, Compositions and Methods for the Treatment of CREB-dependent Diseases | CREBBP, CREB1, ATF1 | NPC1 1963/4885RAB9A 3090/4885MEN1 1241/4885 |
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | NPC1 3686/4885RAB9A 3619/4885MEN1 2345/4885 |
| US-20230073777-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | NPC1 4121/4885RAB9A 3414/4885MEN1 3103/4885 |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | NPC1 4121/4885RAB9A 3414/4885MEN1 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.